Evidence map›Paper›PMID 25187652›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2014

Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-γ for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages.

Finlay W McNab, John Ewbank, Ashleigh Howes, Lucia Moreira-Teixeira, Anna Martirosyan, Nico Ghilardi, Margarida Saraiva, Anne O'Garra

Open access · hybridAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 195 citations in OpenAlex.

  1. Trial
  2. Article
  3. Restricted MHC-II trafficking inbioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Polymorphisms in IRF3 exon 1 influence the immune response to Brucella infection in small ruminants.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Genome-wide screen inbioRxiv : the preprint server for biology · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Finlay W McNabDivision of Immunoregulation, Medical Research Council National Institute for Medical Research, London NW7 1AA, United Kingdom; finlay.x.mcnab@gsk.com.
John EwbankDivision of Immunoregulation, Medical Research Council National Institute for Medical Research, London NW7 1AA, United Kingdom;
Ashleigh HowesDivision of Immunoregulation, Medical Research Council National Institute for Medical Research, London NW7 1AA, United Kingdom;
Lucia Moreira-TeixeiraDivision of Immunoregulation, Medical Research Council National Institute for Medical Research, London NW7 1AA, United Kingdom; Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, 4710-057 Braga, Portugal; Life and Health Sciences Research Institute and Biomaterials, Biodegradables and Biomimetics Research Group, Portugal Government Associate Laboratory, 4710-057 Braga/Guimarães, Portugal; and.
Anna MartirosyanDivision of Immunoregulation, Medical Research Council National Institute for Medical Research, London NW7 1AA, United Kingdom;
Nico GhilardiDepartment of Immunology, Genentech, Inc., South San Francisco, CA 94080.
Margarida SaraivaLife and Health Sciences Research Institute, School of Health Sciences, University of Minho, 4710-057 Braga, Portugal; Life and Health Sciences Research Institute and Biomaterials, Biodegradables and Biomimetics Research Group, Portugal Government Associate Laboratory, 4710-057 Braga/Guimarães, Portugal; and.
Anne O'GarraDivision of Immunoregulation, Medical Research Council National Institute for Medical Research, London NW7 1AA, United Kingdom;
The Francis Crick Institute · GBUniversity of Minho · PTGeneral Medical Council · GBSunesis (United States) · US

Funding

European Research Council 294682Medical Research Council MC_U117565642Medical Research Council U117565642
6 · The paper itself

Abstract

Tuberculosis, caused by the intracellular bacterium Mycobacterium tuberculosis, currently causes ∼1.4 million deaths per year, and it therefore remains a leading global health problem. The immune response during tuberculosis remains incompletely understood, particularly regarding immune factors that are harmful rather than protective to the host. Overproduction of the type I IFN family of cytokines is associated with exacerbated tuberculosis in both mouse models and in humans, although the mechanisms by which type I IFN promotes disease are not well understood. We have investigated the effect of type I IFN on M. tuberculosis-infected macrophages and found that production of host-protective cytokines such as TNF-α, IL-12, and IL-1β is inhibited by exogenous type I IFN, whereas production of immunosuppressive IL-10 is promoted in an IL-27-independent manner. Furthermore, much of the ability of type I IFN to inhibit cytokine production was mediated by IL-10. Additionally, type I IFN compromised macrophage activation by the lymphoid immune response through severely disrupting responsiveness to IFN-γ, including M. tuberculosis killing. These findings describe important mechanisms by which type I IFN inhibits the immune response during tuberculosis.

Indexed as

AnimalsInterferon-gammaInterferon Type IInterleukin-10Interleukin-12Interleukin-1betaInterleukinsMacrophage ActivationMacrophagesMiceMice, KnockoutMycobacterium tuberculosisTuberculosisTumor Necrosis Factor-alphaIL10 protein, mouseIL1B protein, mouseIl27 protein, mouseInterferon-gammaInterferon Type IInterleukin-10Interleukin-12Interleukin-1betaInterleukinsTumor Necrosis Factor-alpha

Identifiers

PMID25187652
PMCPMC4170673
OpenAlexW2118194631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.